FDA grants priority review to Lucentis for diabetic retinopathy

The U.S. Food and Drug Administration has granted priority review of Lucentis for the treatment of diabetic retinopathy, according to a Genentech press release. The company’s supplemental Biologics License Application was submitted on Aug. 7, 2014, based on results from the RISE and RIDE phase 3 trials, and an action date of February 6, 2015 has been scheduled.